Among all these, anti PD-1/PD-L1 therapy is one of the most studied immune checkpoint blockade therapies in cancer, and it has been approved to treat a wide range of cancer types, including blood, skin, lung, liver, bladder, and kidney cancers (74). Here, CD274 is linked to cancer.